Immune modulating effects of receptor interacting protein 2 (RIP2) in autoinflammation and immunity

• Published in: Clinical immunology (Orlando, Fla.) Fla.), 2021-02, Vol.223, p.108648-108648, Article 108648
• Main Authors: Hofmann, Sigrun Ruth, Girschick, Leonie, Stein, Robert, Schulze, Felix
• Format: Article
• Language: English
• Subjects: Apoptosis-associated speck-like protein containing a CARD (ASC); Caspase-1; IL-1β; Inflammasome; Interleukin-1 converting enzyme; NLRP3; NOD1; NOD2; RIPK2
• ISSN: 1521-6616; 1521-7035
• DOI: 10.1016/j.clim.2020.108648

Receptor-interacting protein 2 (RIP2) is a kinase that is involved in downstream signaling of nuclear oligomerization domain (NOD)-like receptors NOD1 and 2 sensing bacterial peptidoglycans. RIP2-deficiency or targeting of RIP2 by pharmaceutical inhibitors partially ameliorates inflammatory diseases by reducing pro-inflammatory signaling in response to peptidoglycans. However, RIP2 is widely expressed and interacts with several other proteins suggesting additional functions outside the NOD-signaling pathway. In this review, we discuss the immunological functions of RIP2 and its possible role in autoinflammation and immunity. •RIP2 plays essential roles in the regulation of innate immune signaling.•inflammatory bowel disease is the most associated pathology with NOD-RIP2 signaling.•XIAP antagonists and RIP2 kinase inhibitors are efficient in targeting the NOD2 signaling pathway.